Mayo Clinic proceedings. Innovations, quality & outcomes最新文献

{"title":"Collaborative Diagnostic Conversations Between Clinicians, Patients, and Their Families: A Way to Avoid Diagnostic Errors","authors":"Nataly R. Espinoza Suarez MD ,&nbsp;Ian Hargraves PhD ,&nbsp;Naykky Singh Ospina MD, MSc ,&nbsp;Angela Sivly ,&nbsp;Andrew Majka MD ,&nbsp;Juan P. Brito MD, MSc","doi":"10.1016/j.mayocpiqo.2023.06.001","DOIUrl":"10.1016/j.mayocpiqo.2023.06.001","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the components of the collaborative diagnostic conversations between clinicians, patients, and their families and how deficiencies in these conversations can lead to diagnostic errors.</p></div><div><h3>Patients and Methods</h3><p>We purposively selected 60 video recordings of clinical encounters that included diagnosis conversations. These videos were obtained from the internal medicine, and family medicine services at Mayo Clinic’s campus in Rochester, Minnesota. These clinical encounters were recorded between November 2017, and December 2021, during the conduct of studies aiming at developing or testing shared decision-making interventions. We followed a critically reflective approach model for data analysis.</p></div><div><h3>Results</h3><p>We identified 3 components of diagnostic conversations as follows: (1) recognizing diagnostic situations, (2) setting priorities, and (3) creating and reconciling a diagnostic plan. Deficiencies in diagnostic conversations could lead to framing issues in a way that sets diagnostic activities off in an incorrect or undesirable direction, incorrect prioritization of diagnostic concerns, and diagnostic plans of care that are not feasible, desirable, or productive.</p></div><div><h3>Conclusion</h3><p>We identified 3 clinician-and-patient diagnostic conversation components and mapped them to potential diagnostic errors. This information may inform additional research to identify areas of intervention to decrease the frequency and harm associated with diagnostic errors in clinical practice.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/d5/main.PMC10344690.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychophysiologic Symptom Relief Therapy for Post-Acute Sequelae of Coronavirus Disease 2019","authors":"Michael Donnino MD ,&nbsp;Patricia Howard BS ,&nbsp;Shivani Mehta BA ,&nbsp;Jeremy Silverman BA ,&nbsp;Maria J. Cabrera BA ,&nbsp;Jolin B. Yamin PhD ,&nbsp;Lakshman Balaji MPH ,&nbsp;Katherine M. Berg MD ,&nbsp;Stanley Heydrick PhD ,&nbsp;Robert Edwards PhD ,&nbsp;Anne V. Grossestreuer PhD, MSc","doi":"10.1016/j.mayocpiqo.2023.05.002","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2023.05.002","url":null,"abstract":"<div><h3>Objective</h3><p>To determine if psychophysiologic symptom relief therapy (PSRT) will reduce symptom burden in patients suffering from post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) who had mild/moderate acute COVID-19 disease without objective evidence of organ injury.</p></div><div><h3>Patients and Methods</h3><p>Twenty-three adults under the age of 60 years with PASC for at least 12 weeks after COVID-19 infection were enrolled in an interventional cohort study conducted via a virtual platform between May 18, 2021 and August 7, 2022. Participants received PSRT during a 13-week (approximately 44-hour) course. Participants were administered validated questionnaires at baseline and at 4, 8, and 13 weeks. The primary outcome was a change in somatic symptoms from baseline, measured using the Somatic Symptom Scale-8, at 13 weeks.</p></div><div><h3>Results</h3><p>The median duration of symptoms before joining the study was 267 days (interquartile range: 144, 460). The mean Somatic Symptom Scale-8 score of the cohort decreased from baseline by 8.5 (95% CI: 5.7-11.4), 9.4 (95% CI: 6.9-11.9), and 10.9 (95% CI: 8.3-13.5) at 4, 8, and 13 weeks, respectively (all <em>P</em>&lt;.001). Participants also experienced statistically significant improvements across other secondary outcomes including changes in dyspnea, fatigue, and pain (all <em>P</em>&lt;.001).</p></div><div><h3>Conclusion</h3><p>PSRT may effectively decrease symptom burden in patients suffering from PASC without evidence of organ injury. The study was registered on <span>clinicaltrials.gov</span><svg><path></path></svg> (NCT 04854772).</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49879418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potentially Preventable Hospitalization Among Adults with Hearing, Vision, and Dual Sensory Loss: A Case and Control Study","authors":"Samantha Ratakonda ,&nbsp;Paul Lin MS ,&nbsp;Neil Kamdar MA ,&nbsp;Michelle Meade PhD ,&nbsp;Michael McKee MD ,&nbsp;Elham Mahmoudi PhD","doi":"10.1016/j.mayocpiqo.2023.06.004","DOIUrl":"10.1016/j.mayocpiqo.2023.06.004","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the risk of potentially preventable hospitalizations (PPHs) among adults with sensory loss. We hypothesized a greater PPH risk among people with a sensory loss (hearing, vision, and dual) compared with controls.</p></div><div><h3>Patients and Methods</h3><p>Using 2007-2016 Medicare fee-for-service claims, this retrospective, case-control study examined the risk of PPH among adults aged 65 years and older with hearing, vision, and dual sensory loss compared with their corresponding counterparts without sensory loss (between June 1, 2022, and February 1, 2023). We ran 3 step-in regression models for the 3 case and control cohorts examining PPH risk. Our generalized linear regression models controlled for age, sex, race, Elixhauser comorbidity count, rurality, neighborhood characteristics, and the number of primary care physicians and hospitals at the county level.</p></div><div><h3>Results</h3><p>People with vision (adjusted odds ratio [aOR], 1.21; 95% CI, 0.84-0.87) and dual sensory loss (aOR, 1.26; 95% CI, 1.14-1.40) showed a higher PPH risks than their corresponding controls. For people with hearing loss, our unadjusted models showed a higher PPH risk (OR, 1.40; 95% CI, 1.38-1.43) but after adjustment, hearing loss showed a protective association against PPH risk (OR, 0.85; 95% CI, 0.84-0.87). Moreover, in all models, annual wellness visits reduced the PPH risk by about half (eg, aOR, 0.54; 95% CI, 0.52-0.55), whereas living in disadvantaged neighborhood increased the PPH risk (eg, aOR, 1.13; 95% CI, 1.10-1.15) for cases and controls.</p></div><div><h3>Conclusion</h3><p>People with vision and dual sensory loss were at greater PPH risk. This study has important health policy implications in reducing PPH and is indicative of a need for more incentivized and systematic approaches to facilitating the use of preventive care, particularly among older adults living in a disadvantaged neighborhood.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/2d/main.PMC10391598.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Closer Look—Who Are We Screening for Lung Cancer?","authors":"Kristine Galang MD ,&nbsp;Efstathia Polychronopoulou MPH, RS, PhD ,&nbsp;Gulshan Sharma MD ,&nbsp;Shawn P.E. Nishi MD","doi":"10.1016/j.mayocpiqo.2023.04.002","DOIUrl":"10.1016/j.mayocpiqo.2023.04.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the characteristics of individuals receiving lung cancer screening (LCS) and identify those with potentially limited benefit owing to coexisting chronic illnesses and/or comorbidities.</p></div><div><h3>Patients and Methods</h3><p>In this retrospective study in the United States, patients were selected from a large clinical database who received LCS from January 1, 2019, through December 31, 2019, with at least 1 year of continuous enrollment. We assessed for potentially limited benefit in LCS defined strictly as not meeting the traditional risk factor inclusion criteria (age &lt;55 years or &gt;80 years, previous computed tomography scan within 11 months before an LCS examination, or a history of nonskin cancer) or liberally as having the potential exclusion criteria related to comorbid life-limiting conditions, such as cardiac and/or respiratory disease.</p></div><div><h3>Results</h3><p>A total of 51,551 patients were analyzed. Overall, 8391 (16.3%) individuals experienced a potentially limited benefit from LCS. Among those who did not meet the strict traditional inclusion criteria, 317 (3.8%) were because of age, 2350 (28%) reported a history of nonskin malignancy, and 2211 (26.3%) underwent a previous computed tomography thorax within 11 months before an LCS examination. Of those with potentially limited benefit owing to comorbidity, 3680 (43.9%) were because of severe respiratory comorbidity (937 [25.5%] with any hospitalization for coronary obstructive pulmonary disease, interstitial lung disease, or respiratory failure; 131 [3.6%] with hospitalization for respiratory failure requiring mechanical ventilation; or 3197 [86.9%] with chronic obstructive disease/interstitial lung disease requiring outpatient oxygen) and 721 (8.59%) with cardiac comorbidity.</p></div><div><h3>Conclusion</h3><p>Up to 1 of 6 low-dose computed tomography examinations may have limited benefit from LCS.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/fb/main.PMC10244365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Care Utilization and Death in Patients With Heart Failure During the COVID-19 Pandemic","authors":"Sheila M. Manemann MPH ,&nbsp;Susan A. Weston MS ,&nbsp;Ruoxiang Jiang BSc ,&nbsp;Nicholas B. Larson PhD ,&nbsp;Véronique L. Roger MD, MPH ,&nbsp;Paul Y. Takahashi MD, MPH ,&nbsp;Alanna M. Chamberlain PhD ,&nbsp;Mandeep Singh MD ,&nbsp;Jennifer L. St. Sauver PhD ,&nbsp;Suzette J. Bielinski PhD, MEd","doi":"10.1016/j.mayocpiqo.2023.04.004","DOIUrl":"10.1016/j.mayocpiqo.2023.04.004","url":null,"abstract":"<div><h3>Objective</h3><p>To compare the 1-year health care utilization and mortality in persons living with heart failure (HF) before and during the coronavirus disease 2019 (COVID-19) pandemic.</p></div><div><h3>Patients and Methods</h3><p>Residents of a 9-county area in southeastern Minnesota aged 18 years or older with a HF diagnosis on January 1, 2019; January 1, 2020; and January 1, 2021, were identified and followed up for 1-year for vital status, emergency department (ED) visits, and hospitalizations.</p></div><div><h3>Results</h3><p>We identified 5631 patients with HF (mean age, 76 years; 53% men) on January 1, 2019, 5996 patients (mean age, 76 years; 52% men) on January 1, 2020, and 6162 patients (mean age, 75 years; 54% men) on January 1, 2021. After adjustment for comorbidities and risk factors, patients with HF in 2020 and patients with HF in 2021 experienced similar risks of mortality compared with those in 2019. After adjustment, patients with HF in 2020 and 2021 were less likely to experience all-cause hospitalizations (2020: rate ratio [RR], 0.88; 95% CI, 0.81-0.95; 2021: RR, 0.90; 95% CI, 0.83-0.97) compared with patients in 2019. Patients with HF in 2020 were also less likely to experience ED visits (RR, 0.85; 95% CI, 0.80-0.92).</p></div><div><h3>Conclusion</h3><p>In this large population-based study in southeastern Minnesota, we observed an approximately 10% decrease in hospitalizations among patients with HF in 2020 and 2021 and a 15% decrease in ED visits in 2020 compared with those in 2019. Despite the change in health care utilization, we found no difference in the 1-year mortality between patients with HF in 2020 and those in 2021 compared with those in 2019. It is unknown whether any longer-term consequences will be observed.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/4a/main.PMC10099179.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9560168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Visit Facilitator Role to Assist Physicians in an Ambulatory Consultative Medical Practice","authors":"Elizabeth A. Gilman MD ,&nbsp;Christopher Aakre MD ,&nbsp;Adam Meyers MBA ,&nbsp;Nerissa Collins MD ,&nbsp;Chrissy VerNess MA ,&nbsp;Brian Dougan MD ,&nbsp;Xiomari Davis MEd ,&nbsp;Lindsey Philpot PhD, MPH ,&nbsp;Priya Ramar MPH ,&nbsp;Ivana Croghan PhD ,&nbsp;Darrell R. Schroeder MS ,&nbsp;Erin Pagel MS, MHI ,&nbsp;Karthik Ghosh MD ,&nbsp;Ryan T. Hurt MD, PhD","doi":"10.1016/j.mayocpiqo.2023.04.003","DOIUrl":"10.1016/j.mayocpiqo.2023.04.003","url":null,"abstract":"<div><h3>Objective</h3><p>To decrease the electronic health record (EHR) clerical burden and improve patient/clinician satisfaction, allied health staff were trained as visit facilitators (VFs) to assist the physician in clinical and administrative tasks.</p></div><div><h3>Patients and Methods</h3><p>From December 7, 2020, to October 11, 2021, patients with complex medical conditions were evaluated by an internal medicine physician in an outpatient general internal medicine (GIM) consultative practice at a tertiary care institution. A VF assisted with specific tasks before, during, and after the clinical visit. Presurvey and postsurvey assessments were performed to understand the effect of the VF on clinical tasks as perceived by the physician.</p></div><div><h3>Results</h3><p>A total of 57 GIM physicians used a VF, and 41 (82%) physicians and 39 (79%) physicians completed the pre-VF and post-VF surveys, respectively. Physicians reported a significant reduction in time reviewing outside materials, updating pertinent information, and creating/modifying EHR orders (<em>P</em>&lt;.05). Clinicians reported improved interactions with patients and on-time completion of clinical documentation. In the pre-VF survey, “too much time spent” was the most common response for reviewing outside material, placing/modifying orders, completing documentation/clinical notes, resolving in-baskets, completing dismissal letters, and completing tasks outside of work hours. In the post-VF survey, “too much time spent” was not the most common answer to any question. Satisfaction improved in all areas (<em>P</em>&lt;.05).</p></div><div><h3>Conclusion</h3><p>VFs significantly reduced the EHR clinical burden and improved GIM physician practice satisfaction. This model can potentially be used in a wide range of medical practices.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/88/main.PMC10196913.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of Positron Emission Tomography Coupled With Computed Tomography for the Diagnosis of Inflammatory Syndrome of Unknown Origin in an Internal Medicine Department","authors":"Xavier Boulu MD ,&nbsp;Isabelle El Esper MD ,&nbsp;Marc-Etienne Meyer MD, PhD ,&nbsp;Pierre Duhaut MD, PhD ,&nbsp;Valery Salle MD, PhD ,&nbsp;Jean Schmidt MD, PhD","doi":"10.1016/j.mayocpiqo.2023.04.001","DOIUrl":"10.1016/j.mayocpiqo.2023.04.001","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the usefulness of positron emission tomography (PET) coupled with computed tomography (CT) in the diagnostic workup for inflammatory syndrome of undetermined origin (IUO) and to determine the diagnostic delay in an internal medicine department.</p></div><div><h3>Patients and methods</h3><p>We retrospectively studied a cohort of patients for whom a PET/CT scan had been prescribed in an indication of IUO in an internal medicine department (Amiens University Medical Center, Amiens, France) between October 2004 and April 2017. The patients were grouped according to the PET/CT findings: very useful (enabling an immediate diagnosis), useful, not useful, and misleading.</p></div><div><h3>Results</h3><p>We analyzed 144 patients. The median (interquartile range) age was 67.7 years (55.8-75.8 years). The final diagnosis was an infectious disease in 19 patients (13.2%), cancer in 23 (16%), inflammatory disease in 48 (33%), and miscellaneous diseases in 12 (8.3%). No diagnosis was made in 29.2% of the cases; half of the remaining had a spontaneously favorable outcome. Fever was observed in 63 patients (43%). Positron emission tomography coupled with CT was determined to be very useful in 19 patients (13.2%), useful in 37 (25.7%), not useful in 63 (43.7%), and misleading in 25 (17.4%). The median diagnostic delay (ie, the time interval between the first admission and a confirmed diagnosis) was significantly shorter in the useful (71 days [38-170 days]) and very useful (55 days [13-79 days]) groups than that in the not useful group (175 days [51-390 days]; P&lt;.001). The median time interval between the PET/CT scan and the diagnosis was twice as long in the not useful group than that in the pooled misleading, useful, or very useful groups (P=.03). In a univariate analysis, the poor overall condition (P=.007) and the absence of fever (P=.005) were predictive of usefulness of PET/CT.</p></div><div><h3>Conclusion</h3><p>Positron emission tomography coupled with CT seems to be useful in the diagnosis of IUO and might shorten the diagnostic delay.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/a1/main.PMC10189090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations of Chest Radiography in Diagnosing Subclinical Pulmonary Tuberculosis in Canada","authors":"Richard Long MD ,&nbsp;Angela Lau MD, MSc ,&nbsp;James Barrie MD ,&nbsp;Christopher Winter MD ,&nbsp;Gavin Armstrong MD ,&nbsp;Mary Lou Egedahl BScN ,&nbsp;Alexander Doroshenko MD, MPH","doi":"10.1016/j.mayocpiqo.2023.03.003","DOIUrl":"10.1016/j.mayocpiqo.2023.03.003","url":null,"abstract":"<div><p>Subclinical pulmonary tuberculosis (PTB) is defined as “…a state of disease due to viable <em>Mycobacterium tuberculosis</em> that does not cause TB-related symptoms but does cause other abnormalities that can be detected using existing radiologic and mycobacteriologic assays.” In high-income countries, subclinical PTB is usually diagnosed during active case finding, is acid-fast bacilli smear negative, and associated with minimal or no lung parenchymal abnormality on chest radiograph. In the absence of symptoms, the epidemiologic risk of TB and chest radiograph are critical to making the diagnosis. In a cohort of 327 patients with subclinical PTB, we address the question—how well field radiologists perform at identifying features important to the diagnosis of PTB, the presence or absence of which have been established by a panel of expert radiologists? Although not performing badly compared with this “gold standard,” field readers were nevertheless susceptible to overread or underread films and miss key diagnostic features, such as the presence of a lung parenchymal abnormality, typical pattern, or cavitation. In the context of active case finding during which most patients with subclinical PTB are discovered, limitations of the chest radiograph need to be recognized, and sputum, ideally induced, should be submitted regardless of the radiographic findings.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/0b/main.PMC10165135.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9806427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Performance of a Commercially Available Artificial Intelligence Algorithm for Automated Detection of Pulmonary Embolism on Contrast-Enhanced Computed Tomography and Computed Tomography Pulmonary Angiography in Patients With Coronavirus Disease 2019","authors":"Karim A. Zaazoue MD ,&nbsp;Mathew R. McCann MD ,&nbsp;Ahmed K. Ahmed MD, MSc ,&nbsp;Isabel O. Cortopassi MD ,&nbsp;Young M. Erben MD ,&nbsp;Brent P. Little MD ,&nbsp;Justin T. Stowell MD ,&nbsp;Beau B. Toskich MD ,&nbsp;Charles A. Ritchie MD","doi":"10.1016/j.mayocpiqo.2023.03.001","DOIUrl":"10.1016/j.mayocpiqo.2023.03.001","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the performance of a commercially available artificial intelligence (AI) algorithm for the detection of pulmonary embolism (PE) on contrast-enhanced computed tomography (CT) scans in patients hospitalized for coronavirus disease 2019 (COVID-19).</p></div><div><h3>Patients and Methods</h3><p>Retrospective analysis was performed of all contrast-enhanced chest CT scans of patients admitted for COVID-19 between March 1, 2020 and December 31, 2021. Based on the original radiology reports, all PE-positive examinations were included (n=527). Using a reversed-flow single-gate diagnostic accuracy case-control model, a randomly selected cohort of PE-negative examinations (n=977) was included. Pulmonary parenchymal disease severity was assessed for all the included studies using a semiquantitative system, the total severity score. All included CT scans were sent for interpretation by the commercially available AI algorithm, Aidoc. Discrepancies between AI and original radiology reports were resolved by 3 blinded radiologists, who rendered a final determination of indeterminate, positive, or negative.</p></div><div><h3>Results</h3><p>A total of 78 studies were found to be discrepant, of which 13 (16.6%) were deemed indeterminate by readers and were excluded. The sensitivity and specificity of AI were 93.2% (95% CI, 90.6%-95.2%) and 99.6% (95% CI, 98.9%-99.9%), respectively. The accuracy of AI for all total severity score groups (mild, moderate, and severe) was high (98.4%, 96.7%, and 97.2%, respectively). Artificial intelligence was more accurate in PE detection on CT pulmonary angiography scans than on contrast-enhanced CT scans (<em>P</em>&lt;.001), with an optimal Hounsfield unit of 362 (<em>P</em>=.048).</p></div><div><h3>Conclusion</h3><p>The AI algorithm demonstrated high sensitivity, specificity, and accuracy for PE on contrast-enhanced CT scans in patients with COVID-19 regardless of parenchymal disease. Accuracy was significantly affected by the mean attenuation of the pulmonary vasculature. How this affects the legitimacy of the binary outcomes reported by AI is not yet known.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9302391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Determinants of Health and Mortality After Premature and Non-premature Acute Coronary Syndrome","authors":"Sagar B. Dugani MD, PhD, MPH ,&nbsp;Mohammad Zubaid MB ChB ,&nbsp;Wafa Rashed MBBS ,&nbsp;Marlene E. Girardo MS ,&nbsp;Zuhur Balayah MSc ,&nbsp;Samia Mora MD, MHS ,&nbsp;Alawi A. Alsheikh-Ali MD, MSc","doi":"10.1016/j.mayocpiqo.2023.03.002","DOIUrl":"10.1016/j.mayocpiqo.2023.03.002","url":null,"abstract":"<div><h3>Objective</h3><p>To describe and compare the determinants of 1-year mortality after premature vs non-premature acute coronary syndrome (ACS).</p></div><div><h3>Patients and Methods</h3><p>Participants presenting with ACS were enrolled in a prospective registry of 29 hospitals in 4 countries, from January 22, 2012 to January 22, 2013, with 1-year of follow-up data. The primary outcome was all-cause 1-year mortality after premature ACS (men aged &lt;55 years and women aged &lt;65 years) and non-premature ACS (men aged ≥55 years and women aged ≥65 years). The associations between the baseline patient characteristics and 1-year mortality were analyzed in models adjusting for the Global Registry of Acute Coronary Events (GRACE) score and reported as adjusted odds ratio (aOR) (95% CI).</p></div><div><h3>Results</h3><p>Of the 3868 patients, 43.3% presented with premature ACS that was associated with lower 1-year mortality (5.7%) than those with non-premature ACS. In adjusted models, women experienced higher mortality than men after premature (aOR, 2.14 [1.37-3.41]) vs non-premature ACS (aOR, 1.28 [0.99-1.65]) (<em>P</em>_interaction=.047). Patients lacking formal education vs any education had higher mortality after both premature (aOR, 2.92 [1.87-4.61]) and non-premature ACS (aOR, 1.78 [1.36-2.34]) (<em>P</em>_interaction=.06). Lack of employment vs any employment was associated with approximately 3-fold higher mortality after premature and non-premature ACS (<em>P</em>_interaction=.72). Using stepwise logistic regression to predict 1-year mortality, a model with GRACE risk score and 4 characteristics (education, employment, body mass index [kg/m²], and statin use within 24 hours after admission) had higher discrimination than the GRACE risk score alone (area under the curve, 0.800 vs 0.773; <em>P</em>_comparison=.003).</p></div><div><h3>Conclusion</h3><p>In this study, women, compared with men, had higher 1-year mortality after premature ACS. The social determinants of health (no formal education or employment) were strongly associated with higher 1-year mortality after premature and non-premature ACS, improved mortality prediction, and should be routinely considered in risk assessment after ACS.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/32/main.PMC10160579.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9437973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}